Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Merger

Thumbnail
January 12, 2021

Medtech deal-making stands firm in difficult times

It takes more than a pandemic to stop medical device companies merging.

Thumbnail
January 06, 2021

Astrazeneca shows megamergers were still possible in 2020

One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.

Article image
Vantage logo
January 06, 2021

Pixium and Second Sight see eye to eye

Article image
Vantage logo
August 25, 2020

Yumanity finds a shell in Proteostasis

Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.

Article image
Vantage logo
August 11, 2020

Bayer hopes to sweeten its outlook with some Kandy

Article image
Vantage logo
August 05, 2020

Philips spends big in-house while Becton favours buying

The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.

Article image
Vantage logo
July 13, 2020

Biopharma takeovers show quantity, if not quality

Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.

Article image
Vantage logo
July 09, 2020

Medical device mergers on pause

2019 was an average year for medtech M&A. 2020, not so much.

Article image
Vantage logo
June 03, 2020

Chinook marks an ignominious end for Sting

Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.

Article image
Vantage logo
May 05, 2020

Alexion goes in a new direction with $1.4bn Portola buy

Alexion’s move on the anticoagulant reversal specialist is not the most intuitive deal – but is 2020’s second biggest so far.

Article image
Vantage logo
April 07, 2020

Biopharma acquisitions slow, but it's not Covid-19's fault yet

Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.